可溶性生长刺激表达因子-2对不同类型冠心病患者远期预后的影响Soluble ST2 level in coronary artery disease: relation to adverse outcome
王江友,陈涵,苏晞,李浪
摘要(Abstract)：
目的探讨可溶性生长刺激表达因子-2(s ST2)对不同类型冠心病[稳定型心绞痛(SAP)、不稳定型心绞痛(UAP)、非ST段抬高心肌梗死(NSTEMI)及ST段抬高心肌梗死(STEMI)]患者长期预后的影响。方法纳入212例冠心病患者(62例SAP、48例UAP、50例NSTEMI及52例STEMI),平均随访22个月;对照组为可疑心绞痛行冠状动脉造影排除冠心病的患者50例。血浆s ST2水平用酶联免疫吸附法测定。结果冠状动脉造影前STEMI组患者s ST2水平[(486.39±68.26)ng/L]高于其他4组患者,且呈动态变化,心肌梗死后12 h达到峰值[(594.27±74.36)ng/L],24 h下降至(392.75±82.89)ng/L,但仍高于其他4组;与肌钙蛋白I呈正相关(r=0.576,P<0.001)。对照组s ST2水平与SAP组患者表达水平相当[(156.75±38.56)ng/L比(159.68±42.65)ng/L,P>0.05];冠状动脉造影前s ST2水平比较,NSTEMI组患者[(315.63±37.56)ng/L比(486.39±68.26)ng/L,P<0.001]、UAP组患者[(216.29±36.57)ng/L比(486.39±68.26)ng/L,P<0.01]均显著低于STEMI组患者。随访期间,18例(8.5%,18/212)患者死亡,32例(15.1%,32/212)患者发生复合临床终点事件(包括全因死亡、再发心肌梗死及心脏原因再次入院)。18例死亡患者血浆s ST2水平明显高于194例非死亡患者[(516.36±49.38)ng/L比(237.64±37.69)ng/L,P<0.001]。在不同冠心病阶段,s ST2仅能预测STEMI患者的死亡风险。结论 s ST2能够通过表达水平高低反映冠心病不同阶段,并且与STEMI患者长期预后相关。
关键词(KeyWords)： 可溶性生长刺激表达因子-2;稳定型心绞痛;不稳定型心绞痛;非ST段抬高心肌梗死;ST段抬高心肌梗死
基金项目(Foundation):
作者(Author): 王江友,陈涵,苏晞,李浪
参考文献(References)：
- [1]Kakkar R,Lee RT.The IL-33/ST2 pathway:therapeutic target and novel biomarker.Nat Rev Drug Discov,2008,7(10):827-840.
- [2]Schmitz J,Owyang A,Oldham E,et al.IL-33,an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2and induces T helper type 2-associated cytokines.Immunity,2005,23(5):479-490.
- [3]Demyanets S,Kaun C,Pentz R,et al.Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature.J Mol Cell Cardiol,2013,60:16-26.
- [4]Weinberg EO,Shimpo M,De Keulenaer GW,et al.Expression and regulation of ST2,an interleukin-1 receptor family member,in cardiomyocytes and myocardial infarction.Circulation,2002,106(23):2961-2966.
- [5]Shimpo M,Morrow DA,Weinberg EO,et al.Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction.Circulation,2004,109(18):2186-2190.
- [6]Kohli P,Bonaca MP,Kakkar R,et al.Role of ST2 in non-STelevation acute coronary syndrome in the MERLIN-TIMI 36 trial.Clin Chem,2012,58(1):257-266.
- [7]Wang TJ,Wollert KC,Larson MG,et al.Prognostic utility of novel biomarkers of cardiovascular stress:the Framingham Heart Study.Circulation,2012,126(13):1596-1604.
- [8]Zhang K,Zhang XC,Mi YH,et al.Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction.Chin Med J(Engl),2013,126(19):3628-3631.
- [9]Tsapaki A,Zaravinos A,Apostolakis S,et al.Genetic variability of the distal promoter of the ST2 gene is associated with angiographic severity of coronary artery disease.J Thromb Thrombolysis,2010,30(3):365-371.
- [10]Mildner M,Storka A,Lichtenauer M,et al.Primary sources and immunological prerequisites for s ST2 secretion in humans.Cardiovasc Res,2010,87(4):769-777.
- [11]Bandara G,Beaven MA,Olivera A,et al.Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.Eur J Immunol,2015,45(11):3034-3044.
- [12]Moore SA,Januzzi JL,Jr.Found in translation soluble ST2 and heart disease.J Am Coll Cardiol,2010,55(3):251-253.
- [13]Pascual-Figal DA,Ordonez-Llanos J,Tornel PL,et al.Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.J Am Coll Cardiol,2009,54(23):2174-2179.
- [14]Shah KB,Kop WJ,Christenson RH,et al.Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction.Clin Chem,2011,57(6):874-882.